Method for distinguishing between head and neck squamous cell carcinoma and lung squamous cell carcinoma
View Patent ↗The present invention is a method distinguishing between head and neck squamous cell carcinoma and lung squamous cell carcinoma. In particular, a 10-gene classifier has been identified which can be used to distinguish between primary squamous cell carcinoma of the lung and metastatic head and neck squamous cell carcinoma. These genes include CXCL13, COL6A2, SFTPB, KRT14, TSPYL5, TMP3, KLK10, MMP1, GAS1, and MYH2. A panel of one or more of these genes, or proteins encoded thereby, can be used for early diagnosis and selection of an appropriate therapeutic treatment.
1. A kit for distinguishing between head and neck squamous cell carcinoma and lung squamous cell carcinoma comprising polynucleotides encoding the full lengths of CXCL13, COL6A2, SFTPB, KRT14, TSPYL5, TMP3, KLK10, MMP1, GAS1, and MYH2 selected as biomarkers for distinguishing between head and neck squamous cell carcinoma and lung squamous cell carcinoma.
2. The kit of claim 1 , wherein the lung squamous cell carcinoma is a primary lung squamous cell carcinoma and the head and neck squamous cell carcinoma is metastatic.
3. A method for determining whether a tumor sample comprises head and neck squamous cell carcinoma or lung squamous cell carcinoma comprising determining polynucleotide expression levels for CXCL13, COL6A2, SFTPB, KRT14, TSPYL5, TMP3, KLK10, MMP1, GAS1, and MYH2 in a tumor sample from head and neck squamous cell carcinoma tissue or lung squamous cell tissue of a patient having head and neck squamous cell carcinoma or lung squamous cell carcinoma; and comparing said levels to control polynucleotide expression levels of CXCL13, COL6A2, SFTPB, KRT14, TSPYL5, TMP3, KLK10, MMP1, GAS1, and MYH2 in tumor tissue from head and neck squamous cell carcinoma tissue and to control polynucleotide expression levels of CXCL13, COL6A2, SFTPB, KRT14, TSPYL5, TMP3, KLK10, MMP1, GAS1, and MYH2 in tumor tissue from lung squamous cell carcinoma tissue, wherein, as compared to said controls, higher polynucleotide expression levels of CXCL13, COL6A2, KRT14, TMP3, KLK10, MMP1, GAS1, and MYH2 indicate that said tumor sample comprises head and neck squamous cell carcinoma and higher polynucleotide expression levels of SFTPB and TSPYL5 indicate that said tumor sample comprises lung squamous cell carcinoma.
4. The method of claim 3 , wherein the lung squamous cell carcinoma is a primary lung squamous cell carcinoma and the head and neck squamous cell carcinoma is metastatic.